Table 2 Predicted HLA II binding profile of conserved and experimentally verified HCMV-specific CD4 T cell epitopes
From: Computational assembly of a human Cytomegalovirus vaccine upon experimental epitope legacy
Epitope | Antigen gene | Antigen accession | a HLA II restriction | b Extended HLA II restriction | c PPC (%) |
|---|---|---|---|---|---|
SIYVYALPLKMLNIP | UL83 | Q6SW59 | DRB1*07, DRB1*15:01 | DRB1*01:01, DRB1*03:01, DRB1*07:01, DRB1*11:01, DRB1*15:01 | 63.95 |
KLFMHVTLGSDVEEDLTMTR | UL83 | Q6SW59 | DRB1*03 | DRB1*03:01, DRB1*04:05, DQA1*05:01/ DQB1*02:01, DQA1*05:01/ DQB1*03:01 | 48.03 |
LPVADAVIHASGKQMWQARL | UL83 | Q6SW59 | DRB1*03 | DRB1*01:01, DQA1*05:01/ DQB1*02:01, DQA1*05:01/ DQB1*03:01 | 42.11 |
GPISGHVLKAVFSRG | UL83 | Q6SW59 | HLA class II | DRB1*01:01, DQA1*05:01/ DQB1*02:01, DQA1*05:01/ DQB1*03:01 | 42.11 |
CSMENTRATKMQVIG | UL83 | Q6SW59 | HLA class II | DRB1*07:01, DQA1*01:02/ DQB1*06:02 | 37.99 |
FTSHEHFGLLCPKSI | UL83 | Q6SW59 | HLA class II | DRB1*01:01, DRB1*07:01, DRB1*09:01, DRB5*01:01 | 34.02 |
YQEFFWDANDIYRIF | UL83 | Q6SW59 | DRB1*01 | DRB1*04:01, DRB3*01:01, DQA1*01:01/ DQB1*05:01 | 27.69 |
RNGFTVLCPKNMIIK | UL83 | Q6SW59 | HLA-DR | DRB1*01:01, DRB1*09:01, DRB1*11:01 | 27.09 |
RLLQTGIHVRVSQPS | UL83 | Q6SW59 | DRB1*15, DQA1*01:02/ DQB1*06:02 | DQA1*01:02/ DQB1*06:02 | 24.17 |
LRQYDPVAALFFFDI | UL83 | Q6SW59 | DRB1*07 | DRB1*07:01, DRB1*09:01, | 24.01 |
LPLKMLNIPSINVHH | UL83 | Q6SW59 | DRB1*03 | DRB1*01:01, DRB1*04:04, DRB1*09:01 | 21.87 |
QNLKYQEFFWDANDI | UL83 | Q6SW59 | HLA class II | DRB5*01:01, DQA1*01:01/ DQB1*05:01 | 18.56 |
EPDVYYTSAFVFPTK | UL83 | Q6SW59 | DRB1*07 | DRB1*15:01 | 18.41 |
MLDVAFTSHEHFGLL | UL83 | Q6SW59 | HLA class II | DRB1*07:01 | 18.23 |
SDVEEDLTMTRNPQP | UL83 | Q6SW59 | DRB1*03 | DRB1*03:01 | 17.84 |
AGILARNLVPMVATV | UL83 | Q6SW59 | DRB1*11, DRB3*02:02 | DRB1*01:01, DRB3*02:02 | 11.53 |
EHPTFTSQYRIQGKL | UL83 | Q6SW59 | DRB1*11:01 | DRB1*11:01 | 10.54 |
TSQYRIQGKLEYRHT | UL83 | Q6SW59 | DRB1*04, DRB1*13 | DRB1*11:01 | 10.54 |